Clinical relations of methotrexate pharmacokinetics in the treatment for pediatric osteosarcoma

Journal of Cancer Research and Clinical Oncology

Volumn 138, Issue 10, 2012, Pages 1697-1702

  Hegyi, Marta ^a   Gulácsi, Ágnes ^a   Cságoly, Edit ^b   Csordás, Katalin ^a   Eipel, Olivér T ^a   Erdélyi, Dániel J ^a,b   Müller, Judit ^a   Nemes, Karolina ^a   Lautner Csorba, Orsolya ^b   Kovács, Gábor T ^a  

^a SEMMELWEIS UNIVERSITY   (Hungary)

^b SEMMELWEIS UNIVERSITY   (Hungary)

Author keywords

Methotrexate; Osteosarcoma; Pharmacokinetics; Toxicity

Indexed keywords

ALANINE AMINOTRANSFERASE; BILIRUBIN; CARBOPLATIN; CISPLATIN; CREATININE; DOXORUBICIN; ETOPOSIDE; FOLINIC ACID; IFOSFAMIDE; METHOTREXATE;

ADOLESCENT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; AREA UNDER THE CURVE; ARTICLE; BILIRUBIN BLOOD LEVEL; BONE MARROW TOXICITY; CHILD; CORRELATION ANALYSIS; CREATININE BLOOD LEVEL; DISEASE SEVERITY; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG HALF LIFE; DRUG MEGADOSE; EVENT FREE SURVIVAL; FEMALE; HEMATOLOGICAL PARAMETERS; HEPATOBILIARY PARAMETERS; HIGH RISK PATIENT; HUMAN; LEUKOCYTE COUNT; LIVER TOXICITY; MAJOR CLINICAL STUDY; MALE; MULTIPLE CYCLE TREATMENT; NEPHROTOXICITY; OSTEOSARCOMA; OVERALL SURVIVAL; PHARMACOLOGICAL PARAMETERS; PRIORITY JOURNAL; RENAL SYSTEM PARAMETERS; RETROSPECTIVE STUDY; SURVIVAL RATE; TREATMENT DURATION; TREATMENT RESPONSE;

ADOLESCENT; ANTIMETABOLITES, ANTINEOPLASTIC; BONE MARROW; BONE NEOPLASMS; DISEASE-FREE SURVIVAL; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; LIVER; METHOTREXATE; OSTEOSARCOMA; RETROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 84866735479     PISSN: 01715216     EISSN: 14321335     Source Type: Journal    
DOI: 10.1007/s00432-012-1214-2     Document Type: Article

References (24)

1. Aquerreta I, Aldaz A, Giraldez J, Sierrasesumaga L (2004) Metho-trexate pharmacokinetics and survival in osteosarcoma. Pediatr Blood Cancer 42(1):52-58. doi:10.1002/pbc.10443
2. Bacci G, Picci P, Avella M, Dallari D, Ferrari S, Prasad R, Di Scioscio M, Malaguti C, Caldora P (1990) The importance of dose-intensity in neoadjuvant chemotherapy of osteosarcoma: a retrospective analysis of high-dose methotrexate, cisplatinum and adriamycin used preoperatively. J Chemother 2(2):127-135
3. Bacci G, Ferrari S, Delepine N, Bertoni F, Picci P, Mercuri M, Bacchini P, Brach del Prever A, Tienghi A, Comandone A, Campanacci M (1998) Predictive factors of histologic response to primary chemotherapy in osteosarcoma of the extremity: study of 272 patients preoperatively treated with high-dose methotrexate, doxorubicin, and cisplatin. J Clin Oncol 16(2):658-663
4. Bacci G, Ferrari S, Longhi A, Forni C, Giacomini S, Lari S, Versari M (2001) Relationship between dose-intensity of treatment and outcome for patients with osteosarcoma of the extremity treated with neoadjuvant chemotherapy. Oncol Rep 8(4):883-888
5. Bacci G, Loro L, Longhi A, Bertoni F, Bacchini P, Versari M, Picci P, Serra M (2006) No correlation between methotrexate serum level and histologic response in the pre-operative treatment of extremity osteosarcoma. Anticancer Drugs 17(4):411-415. doi: 10.1097/01.cad.0000203379.14738.d9
6. Bielack S, Jurgens H, Jundt G, Kevric M, Kuhne T, Reichardt P, Zoubek A, Werner M, Winkelmann W, Kotz R (2009) Osteo-sarcoma: the COSS experience. Cancer Treat Res 152:289-308. doi:10.1007/978-1-4419-0284-9-15
7. Bieling P, Bielack S, Delling G, Jurgens H, Kotz R, Dose C, Astheimer H, Exner G, Gadner H, Graf N et al (1991) Neoadjuvant chemotherapy of osteosarcoma. Preliminary results of the cooperative COSS-86 osteosarcoma study. Klin Padiatr 203(4):220-230. doi:10.1055/s-2007-1025433
8. Bleyer WA (1978) The clinical pharmacology of methotrexate: new applications of an old drug. Cancer 41(1):36-51
9. Bleyer WA (1989) New vistas for leucovorin in cancer chemotherapy. Cancer 63(6 Suppl):995-1007
10. Comandone A, Passera R, Boglione A, Tagini V, Ferrari S, Cattel L (2005) High dose methotrexate in adult patients with osteosar-coma: clinical and pharmacokinetic results. Acta Oncol 44(4):406-411. doi:10.1080/02841860510029770
11. Crews KR, Liu T, Rodriguez-Galindo C, Tan M, Meyer WH, Panetta JC, Link MP, Daw NC (2004) High-dose methotrexate pharma-cokinetics and outcome of children and young adults with osteosarcoma. Cancer 100(8):1724-1733. doi:10.1002/cncr. 20152
12. Delepine N, Delepine G, Cornille H, Brion F, Arnaud P, Desbois JC (1995) Dose escalation with pharmacokinetics monitoring in methotrexate chemotherapy of osteosarcoma. Anticancer Res 15(2):489-494
13. Delepine N, Delepine G, Bacci G, Rosen G, Desbois JC (1996) Influence of methotrexate dose intensity on outcome of patients with high grade osteogenic osteosarcoma. Analysis of the literature. Cancer 78(10):2127-2135. doi:10.1002/(SICI)1097-0142(19961115)78:10<2127:AID-CNCR13>3.0.CO;2-0
14. Graf N, Winkler K, Betlemovic M, Fuchs N, Bode U (1994) Methotrexate pharmacokinetics and prognosis in osteosarcoma. J Clin Oncol 12(7):1443-1451
15. Hegyi M, Semsei AF, Jakab Z, Antal I, Kiss J, Szendroi M, Csoka M, Kovacs G (2011) Good prognosis of localized osteosarcoma in young patients treated with limb-salvage surgery and chemotherapy. Pediatr Blood Cancer 57(3):415-422. doi:10.1002/pbc.23172
16. Holmboe L, Andersen AM, Morkrid L, Slordal L, Hall KS (2011) High-dose methotrexate chemotherapy: pharmacokinetics, folate and toxicity in osteosarcoma patients. Br J Clin Pharmacol. doi: 10.1111/j.1365-2125.2011.04054.x
17. Jaffe NTD (1975) Toxicity of high-dose methotrexate (NSC-740) and citrovorum factor (NSC-3590) in osteogenic sarcoma. Cancer Chemother Rep 6:31-36
18. Jaffe N, Gorlick R (2008) High-dose methotrexate in osteosarcoma: let the questions surcease-time for final acceptance. J Clin Oncol 26(27):4365-4366. doi:10.1200/JCO.2007.14.7793
19. Messerschmitt PJ, Garcia RM, Abdul-Karim FW, Greenfield EM, Getty PJ (2009) Osteosarcoma. J Am Acad Orthop Surg 17(8):515-527.
20. Schmiegelow K, Pulczynska M (1990) Prognostic significance of hepatotoxicity during maintenance chemotherapy for childhood acute lymphoblastic leukaemia. Br J Cancer 61(5):767-772
21. Schmiegelow K, Schroder H, Pulczynska MK, Hejl M (1989) Maintenance chemotherapy for childhood acute lymphoblastic leukemia: relation of bone-marrow and hepatotoxicity to the concentration of methotrexate in erythrocytes. Cancer Chemo-ther Pharmacol 25(1):65-69
22. Smeland S, Muller C, Alvegard TA, Wiklund T, Wiebe T, Bjork O, Stenwig AE, Willen H, Holmstrom T, Folleras G, Brosjo O, Kivioja A, Jonsson K, Monge O, Saeter G (2003) Scandinavian Sarcoma Group Osteosarcoma Study SSG VIII: prognostic factors for outcome and the role of replacement salvage chemotherapy for poor histological responders. Eur J Cancer 39(4):488-494
23. Von Hoff DD, Penta JS, Helman LJ, Slavik M (1977) Incidence of drug-related deaths secondary to high-dose methotrexate and citrovorum factor administration. Cancer Treat Rep 61(4):745-748
24. Zelcer S, Kellick M, Wexler LH, Shi W, Sankaran M, Lo S, Healey J, Huvos AG, Meyers PA, Gorlick R (2005) Methotrexate levels and outcome in osteosarcoma. Pediatr Blood Cancer 44(7):638-642. doi:10.1002/pbc.20314